Status:
COMPLETED
The Impact of Menopause on the Development of Heart Failure and Organ Damage of Hypertension
Lead Sponsor:
Polish Mother Memorial Hospital Research Institute
Conditions:
Hypertension
Menopause
Eligibility:
FEMALE
40+ years
Brief Summary
Introduction: The average age of menopause in the Polish population is around 50 years. After the occurrence of the last menstruation in the woman's body there are series of hormonal changes that may ...
Detailed Description
Introduction: The average age of menopause in the Polish population is around 50 years. After the last menstruation a number of hormonal changes occur in the female body: estrogen, ovarian androgens ...
Eligibility Criteria
Inclusion
- About 100 women aged\> 40 years will be included in the study with diagnosed pharmacologically controlled hypertension, including:
- Group I-about 50 women \> 40 years before the onset of menopause Group II - approximately 50 women \> 1 year after the onset of menopause
Exclusion
- unstable hypertension;
- diagnosed heart failure or typical symptoms of heart failure;
- documented: hyperandrogenism, hyperendogenism, insulin resistance, premature ovarian failure, polycystic ovary syndrome;
- previous myocardial infarction;
- diagnosed cardiomyopathy (hypertrophic, dilated, restrictive, puerperal, tachyarrhythmic);
- storage diseases;
- stroke, TIA, an intracerebral bleeding;
- severe hyperthyroidism or hypothyroidism;
- pregnancy or lactation;
- chronic kidney disease in stage IV, V according to NKF and patients undergoing dialysis;
- documented cancer process;
- patient's inability to cooperate and / or give informed consent not to participate in a research;
- alcohol and drug abuse;
- active autoimmune disease;
- taking immunosuppressive, cytostatic drugs, glucocorticoids or antiretroviral drugs;
- bone marrow transplant or other organ transplantation, treatment with blood products during the last 6 months;
- active systemic infection;
- HBV, HCV or HIV infection or a positive result for the presence of HbS antigen or anti-HCV antibodies;
- surgery or serious injury in the last month;
- vaccination interview in the last 3 months;
- patients who have not expressed their informed consent to participate in the study
Key Trial Info
Start Date :
January 22 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT04822857
Start Date
January 22 2019
End Date
December 30 2020
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart Failure Unit, Department of Cardiology and Congenital Malformations of Adults, Polish Mother's Memorial Hospital Research Institute
Lodz, Poland, 93-338